Roullet E, Assuerus V, Gozlan J, Ropert A, Saïd G, Baudrimont M, el Amrani M, Jacomet C, Duvivier C, Gonzales-Canali G
Department of Neurology, Hôpital Saint-Antoine, France.
Neurology. 1994 Nov;44(11):2174-82. doi: 10.1212/wnl.44.11.2174.
A severe multifocal neuropathy caused by cytomegalovirus (CMV-MN) can occur in the late stage of human immunodeficiency virus (HIV) infection. In a retrospective study, we identified 15 consecutive HIV-positive patients with a diagnosis of CMV-MN based on (1) markedly asymmetric neuropathy, (2) fewer than 100 CD4+ cells per mm3, (3) exclusion of other causes of neuropathy, and (4) characteristic CMV cytopathic changes on neuromuscular biopsy (2 patients), positive CSF culture for CMV (2 patients), or clinical improvement on anti-CMV therapy given for concurrent extraneurologic CMV disease (8 patients) or neuropathy (3 patients). All patients were men and had severe immunosuppression (mean CD4+ cell count, 18 per mm3). The initial symptoms were numbness and painful paresthesias showing a patchy, multifocal distribution. After a mean of 11 weeks (range, 1 to 10 months), the patients developed moderate or severe sensorimotor asymmetric neuropathy. Extraneurologic CMV infection occurred in 10 patients before diagnosis. Electrophysiologic studies showed axonal neuropathy and CMV DNA was present in CSF by the polymerase chain reaction (PCR) technique in 90% of patients tested. Fourteen patients showed a marked improvement 1 to 4 weeks after starting ganciclovir or foscarnet therapy. During follow-up on maintenance therapy (13 patients), the neuropathy relapsed in three patients and probable or confirmed CMV encephalitis occurred in five. Twelve patients died during follow-up, at a mean interval of 9.5 months after their first symptoms. These results extend the clinical spectrum of CMV-MN and show that PCR detection of CMV DNA in CSF may be a useful diagnostic marker.
巨细胞病毒引起的严重多灶性神经病(CMV-MN)可发生于人类免疫缺陷病毒(HIV)感染晚期。在一项回顾性研究中,我们确定了15例连续的HIV阳性患者,他们被诊断为CMV-MN,依据为:(1)明显不对称性神经病;(2)每立方毫米CD4+细胞少于100个;(3)排除神经病的其他病因;(4)神经肌肉活检有特征性的CMV细胞病变改变(2例患者)、脑脊液CMV培养阳性(2例患者),或因并发神经系统外CMV疾病(8例患者)或神经病(3例患者)接受抗CMV治疗后临床改善。所有患者均为男性,且有严重免疫抑制(平均CD4+细胞计数为每立方毫米18个)。初始症状为麻木和疼痛性感觉异常,呈斑片状、多灶性分布。平均11周(范围1至10个月)后,患者出现中度或重度感觉运动不对称性神经病。10例患者在诊断前发生了神经系统外CMV感染。电生理研究显示为轴索性神经病,90%接受检测的患者脑脊液中通过聚合酶链反应(PCR)技术检测到CMV DNA。14例患者在开始更昔洛韦或膦甲酸钠治疗后1至4周有明显改善。在维持治疗随访期间(13例患者),3例患者神经病复发,5例发生可能或确诊的CMV脑炎。12例患者在随访期间死亡,自首次出现症状起平均间隔9.5个月。这些结果扩展了CMV-MN的临床谱,表明脑脊液中CMV DNA的PCR检测可能是一种有用的诊断标志物。